March 3, 2026 at 4:01 PM EST PDF Version ARCT-032 (CF) Phase 2 third cohort (28 days, 15 mg) generally safe and well tolerated ARCT-032 permitted to proceed into 12-week Phase 2 study; dosing to begin H1 2026 Cash runway extended into Q2 2028…
March 3, 2026 at 4:01 PM EST
PDF Version
ARCT-032 (CF) Phase 2 third cohort (28 days, 15 mg) generally safe and well tolerated
ARCT-032 permitted to proceed into 12-week Phase 2 study; dosing to begin H1 2026
Cash runway extended into Q2 2028
Investor conference call at 4:30 p.m. ET today
SAN DIEGO--(BUSINESS WIRE)--Mar. 3, 2026-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced its financial results for the fourth quarter and fiscal year 2025, and provided corporate updates.
“Arcturus continues to progress its rare disease therapeutic portfolio. We look forward to aligning with regulators on our clinical development strategy for the ornithine transcarbamylase (OTC) deficiency program, and to initiating our Phase 2, 12‑week cystic fibrosis (CF) study in the first half of 2026,” said Joseph Payne, President & CEO of Arcturus. “We remain firmly committed to advancing our once‑daily inhaled mRNA therapy for people with cystic fibrosis Class I mutations.”
Recent Corporate Highlights
-
Arcturus’ ARCT-032, a once-daily inhaled mRNA therapeutic candidate for CF, is on track to initiate a new 12-week Phase 2 clinical study in H1 2026 enrolling up to 20 Class I CF participants in the U.S. and abroad. The study will assess safety and early clinical benefits, including potential lung function improvements (ppFEV1, LCI), alongside validated quality‑of‑life outcomes and high-resolution computed tomography (HRCT) imaging.
-
Arcturus has completed once-daily dosing of 15 mg of ARCT-032 over 28 days in the third dosing cohort, among four Class I adults with CF, and observed no safety or tolerability issues in this higher dosing cohort.
-
The safety review committee has reviewed all data from the first three 28-day study cohorts (5, 10, 15 mg) and permitted the program to proceed into the Phase 2, 12-week study.
-
Arcturus’ ARCT‑810 program, an mRNA therapeutic candidate for ornithine transcarbamylase (OTC) deficiency, is broadening its development strategy to address the needs of both adults with late‑onset disease and young children affected by the most severe forms of OTC deficiency. The Company is actively engaged in complementary regulatory interactions and strategic planning to support pivotal studies across pediatric and adult populations, including those for whom liver transplantation remains the only current option for survival beyond early childhood. The scheduled Type C regulatory meetings with health authorities, along with the associated feedback, remain on track for the first half of 2026.
-
In January 2026, the UK Medicines and Healthcare products Regulatory Agency (MHRA) granted approval for KOSTAIVE®, a self-amplifying mRNA (sa-mRNA) COVID‑19 vaccine, for use in individuals aged 18 and older.
-
Arcturus continues to develop a self-amplifying mRNA pandemic influenza (A/H5N1) vaccine under its ongoing contract with BARDA. Recent data from an eight-month follow-up period after the first vaccination indicate that all three tested dose levels (1.5, 5, and 12 mcg) elicit a durable immune response against the vaccine's hemagglutinin and neuraminidase components. The data also supports the sa-mRNA platform's ability to induce meaningful cell-mediated immunity. All tested vaccine doses were well tolerated and did not raise safety concerns.
-
Arcturus’ lawsuit against AbbVie Inc., and Capstan Therapeutics, Inc.—filed on September 23, 2025, in the U.S. District Court for the Southern District of California—remains ongoing.
Financial Results for the Fourth Quarter and Fiscal Year 2025
Revenue in conjunction with strategic alliances and collaborations:
Arcturus’ primary revenue streams include license fees, consulting and related technology transfer fees, reservation fees and collaborative payments received from research and development arrangements with pharmaceutical and biotechnology partners. Revenue for the fourth quarter and fiscal year 2025, was $7.2 million and $82.0 million, respectively, representing decreases of $15.6 million and $70.3 million compared to the same periods in 2024. These declines were driven by reductions in revenue from the CSL collaboration, reflecting lower supply agreement activity and a reduced number of development-based milestone achievements as KOSTAIVE® was commercialized.
Operating expenses:
Operating expenses for the fourth quarter and fiscal year 2025 amounted to $38.5 million and $158.3 million, respectively, representing decreases of $17.7 million and $89.7 million compared with the same periods in 2024.
Research and development expenses:
Research and development expenses consist primarily of external manufacturing costs, in vivo research studies and clinical trials performed by contract research organizations, clinical and regulatory consultants, personnel-related expenses, facility-related expenses and laboratory supplies related to conducting research and development activities. Research and development expenses were $24.5 million for the fourth quarter of 2025, compared with $43.8 million for the same period in 2024. The decrease was primarily driven by lower manufacturing costs for the LUNAR-COVID, LUNAR-FLU, and LUNAR-CF programs, as well as reduced clinical trial expenses for LUNAR-COVID and LUNAR-CF. Lower payroll and employee benefits further contributed to the decrease. These reductions were partially offset by higher facilities and equipment costs due to lease impairment in the current period.
Research and development expenses were $112.2 million for fiscal year 2025, compared with $195.2 million for fiscal year 2024. The decrease was primarily driven by lower manufacturing and clinical costs related to the LUNAR-COVID program, reflecting the program’s transition from a development program to the commercial phase. Additional decreases relate to lower manufacturing costs for the LUNAR-CF and LUNAR-FLU programs, as well as lower clinical costs associated with the LUNAR‑OTC program. These reductions were partially offset by higher clinical costs for Phase 2 of the LUNAR-CF program. Additional decreases resulted from lower payroll and benefits expenses following the operational restructuring.
General and Administrative Expenses:
General and administrative expenses primarily consist of salaries and related benefits for executive, administrative, legal and accounting functions and professional fees for legal and accounting services. General and administrative expenses for the fourth quarter of 2025 were $14.0 million compared with $12.4 million for the same period in 2024. The increase in fourth quarter expenses relates to the acceleration of employee stock options.
General and administrative expenses for fiscal year 2025 were $46.1 million compared with $52.8 million for fiscal year 2024. The decrease was primarily due to reduced share-based compensation expense as well as reduced payroll and benefits. We expect general and administrative expenses to continue to decrease slightly during the next twelve months driven by lower share-based compensation costs.
Net Loss:
For the fourth quarter of 2025, Arcturus reported a net loss of $29.1 million, or ($1.03) per diluted share, compared with a net loss of $30.0 million, or ($1.11) per diluted share for the same period in 2024. For fiscal year 2025, Arcturus reported a net loss of $65.8 million, or ($2.40) per diluted share, compared with a net loss of $80.9 million, or ($3.00) per diluted share for fiscal year 2024.
Cash Position and Balance Sheet:
Cash, cash equivalents and restricted cash were $232.8 million as of December 31, 2025, and $293.9 million as of December 31, 2024. Through disciplined execution and a strategic refocus on existing rare disease clinical programs in fiscal year 2025, Arcturus has extended its cash runway into the second quarter of 2028.
Arcturus Therapeutics Fourth Quarter and Fiscal Year 2025 Earnings Conference Call
-
Tuesday, March 3, 2026 @4:30 p.m. ET
-
Domestic: 1-800-274-8461
-
International: 1-203-518-9814
-
Conference ID: ARCTURUS
-
Webcast: Link
Forward Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact included in this press release, are forward-looking statements, including those regarding strategy, future operations, the likelihood of success of the Company’s pipeline (including ARCT-032 and ARCT-810) and partnered programs (including the COVID-19 and flu programs partnered with CSL Seqirus), the likelihood that clinical data, including interim data, will be predictive of future clinical results, the likelihood of and timing for achieving alignment with regulators on the clinical strategy for ARCT-810, plans to broaden the development strategy for ARCT-810, the timing for Type C regulatory meetings for ARCT-810 and feedback therefrom, the likelihood of initiation, and size, scope, and timing, of a Phase 2, 12-week study for ARCT-032, the ongoing development of a self-amplifying mRNA pandemic influenza vaccine under its contract with BARDA, the likelihood that general and administrative expenses will continue to decrease slightly, its current cash position and expected cash burn and runway, and the impact of general business and economic conditions. Arcturus may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in any forward-looking statements such as the foregoing and you should not place undue reliance on such forward-looking statements. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements, including those discussed under the heading "Risk Factors" in Arcturus’ most recent Annual Report on Form 10-K, and in subsequent filings with, or submissions to, the SEC, which are available on the SEC’s website at www.sec.gov. Except as otherwise required by law, Arcturus disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.
About Arcturus
Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed KOSTAIVE®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration with CSL Seqirus, U.S. BARDA for pandemic flu and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus’ pipeline includes RNA therapeutic candidates to potentially treat cystic fibrosis (CF) and ornithine transcarbamylase (OTC) deficiency along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA (siRNA), circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (over 500 patents and patent applications in the U.S., Europe, Japan, China, and other countries). For more information, visit www.ArcturusRx.com. Please connect with us on X and LinkedIn.
| ARCTURUS THERAPEUTICS HOLDINGS INC. AND ITS SUBSIDIARIES CONSOLIDATED BALANCE SHEETS |
| | | |
| | | As of December 31, |
| (in thousands, except per share data) | | 2025 | | 2024 |
| Assets | | | | |
| Current assets: | | | | |
| Cash and cash equivalents | | $ | 230,909 | | | $ | 237,028 | |
| Restricted cash | | | — | | | | 55,000 | |
| Accounts receivable | | | 5,564 | | | | 3,974 | |
| Prepaid expenses and other current assets | | | 4,973 | | | | 9,977 | |
| Total current assets | | | 241,446 | | | | 305,979 | |
| Property and equipment, net | | | 6,736 | | | | 9,531 | |
| Operating lease right-of-use asset | | | 21,081 | | | | 26,674 | |
| Non-current restricted cash | | | 1,885 | | | | 1,885 | |
| Total assets | | $ | 271,148 | | | $ | 344,069 | |
| Liabilities and Stockholders’ Equity | | | | |
| Current liabilities: | | | | |
| Accounts payable | | $ | 4,235 | | | $ | 7,194 | |
| Accrued liabilities | | | 23,898 | | | | 38,781 | |
| Deferred revenue | | | 8,246 | | | | 19,514 | |
| Total current liabilities | | | 36,379 | | | | 65,489 | |
| Deferred revenue, net of current portion | | | — | | | | 12,604 | |
| Operating lease liability, net of current portion | | | 20,784 | | | | 24,998 | |
| Total liabilities | | | 57,163 | | | | 103,091 | |
| Stockholders’ equity: | | | | |
| Common stock: $0.001 par value; 60,000 shares authorized; issued and outstanding shares were 28,414 at December 31, 2025 and 27,000 at December 31, 2024 | | | 28 | | | | 27 | |
| Additional paid-in capital | | | 728,547 | | | | 689,758 | |
| Accumulated deficit | | | (514,590 | ) | | | (448,807 | ) |
| Total stockholders’ equity | | | 213,985 | | | | 240,978 | |
| Total liabilities and stockholders’ equity | | $ | 271,148 | | | $ | 344,069 | |
| ARCTURUS THERAPEUTICS HOLDINGS INC. AND ITS SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS |
| | | |
| | | Year Ended December 31, |
| (in thousands, except per share data) | | 2025 | | 2024 | | 2023 |
| Revenue: | | | | | | |
| Collaboration revenue | | $ | 67,221 | | | $ | 138,389 | | | $ | 157,748 | |
| Grant revenue | | | 14,810 | | | | 13,921 | | | | 9,051 | |
| Total revenue | | | 82,031 | | | | 152,310 | | | | 166,799 | |
| Operating expenses: | | | | | | |
| Research and development, net | | | 112,212 | | | | 195,156 | | | | 192,133 | |
| General and administrative | | | 46,079 | | | | 52,823 | | | | 52,871 | |
| Total operating expenses | | | 158,291 | | | | 247,979 | | | | 245,004 | |
| Loss from operations | | | (76,260 | ) | | | (95,669 | ) | | | (78,205 | ) |
| Gain (loss) from foreign currency | | | 382 | | | | (471 | ) | | | (229 | ) |
| Finance income, net | | | 10,095 | | | | 15,195 | | | | 16,591 | |
| Gain on debt extinguishment | | | — | | | | — | | | | 33,953 | |
| Net loss before income taxes | | | (65,783 | ) | | | (80,945 | ) | | | (27,890 | ) |
| (Benefit) provision for income taxes | | | — | | | | (4 | ) | | | 1,835 | |
| Net loss | | | (65,783 | ) | | | (80,941 | ) | | | (29,725 | ) |
| Net loss per share, basic and diluted | | $ | (2.40 | ) | | $ | (3.00 | ) | | $ | (1.12 | ) |
| Weighted-average shares outstanding, basic and diluted | | | 27,386 | | | | 27,000 | | | | 26,628 | |
| Comprehensive loss | | $ | (65,783 | ) | | $ | (80,941 | ) | | $ | (29,725 | ) |
| ARCTURUS THERAPEUTICS HOLDINGS INC. AND ITS SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) |
| | | |
| | | Three Months Ended |
| | | December 31, |
| (in thousands, except per share data) | | 2025 | | 2024 |
| Revenue: | | | | |
| Collaboration revenue | | $ | 3,081 | | | $ | 21,000 | |
| Grant revenue | | | 4,115 | | | | 1,766 | |
| Total revenue | | | 7,196 | | | | 22,766 | |
| Operating expenses: | | | | |
| Research and development, net | | | 24,476 | | | | 43,780 | |
| General and administrative | | | 14,027 | | | | 12,380 | |
| Total operating expenses | | | 38,503 | | | | 56,160 | |
| Loss from operations | | | (31,307 | ) | | | (33,394 | ) |
| Gain from foreign currency | | | 701 | | | | 171 | |
| Finance income, net | | | 1,523 | | | | 3,214 | |
| Net loss before income taxes | | | (29,083 | ) | | | (30,009 | ) |
| Benefit for income taxes | | | (4 | ) | | | (4 | ) |
| Net loss | | $ | (29,079 | ) | | $ | (30,005 | ) |
| Net loss per share, basic and diluted | | $ | (1.03 | ) | | $ | (1.11 | ) |
| Weighted-average shares outstanding, basic and diluted | | | 28,112 | | | | 27,000 | |
| Comprehensive loss | | $ | (29,079 | ) | | $ | (30,005 | ) |

View source version on businesswire.com: https://www.businesswire.com/news/home/20260303197744/en/
Arcturus TherapeuticsPublic Relations & Investor Relations
Neda Safarzadeh
VP, Head of IR/PR/Marketing
(858) 900-2682
[email protected]
Source: Arcturus Therapeutics Holdings Inc.
ArabicChineseDanishDutchEnglishEspañolFinnishFrenchGermanHebrewHungarianHindiItalianJapaneseKoreanMalayNorwegianSwedishSerbian LatinSerbian CirillicPolishPortugueseTamil
Accessibility Menu
Choose a Safe Browsing Profile
Active
ONOFF
Color Blindness Adjustments
Color adjustment for colorblind users
Selecting a color profile below will make the screen colors more distinct for each profile type.
Red-green color blindness
Deuteranomaly
Protanomaly
Protanopia
Deuteranopia
Blue-yellow color blindness
Tritanopia
Tritanomaly
Other color blindness
Achromatopsia
Achromatomaly
ONOFF
Seizure Safe Mode
Reduces saturation and stops animations
This mode reduces the risk of seizure that result from flashing or blinking animations and risky color combinations by reducing saturation and stopping animations, transitions, and videos.
ONOFF
Visually Impaired Mode
Adjusts screen to assist with visual elements
This mode adjusts visual elements on the screen to assist users with visual impairment
ONOFF
Cognitive Disability Mode
Improves identification of elements.
This mode provides assistive highlighting of titles and links to allow users with cognitive disabilities to identify and navigate page elements.
ONOFF
ADHD/Focus Friendly Mode
Reduces distractions and improves focus
This mode reduces distractions to help users with ADHD and Neurodevelopmental disorders to read, browse, and focus content much easier.
ONOFF
Assistive Navigation Mode
Enables keyboard navigation with screen reader
This mode allows keyboard navigation throughout the page, and includes a screen reader for assistive navigation
Content Control
Readable Font
Dyslexia Font
Highlight Titles
Highlight Links
Text Magnifier
Content Scaling
Reset
Font Size
Reset
Line Height
Reset
Letter Spacing
Reset
Align Left
Align Center
Align Right
Design Control
Dark Contrast
Invert Colors
Light Contrast
Monochrome
High Contrast
High Saturation
Low Saturation
Adjust Text Colors
Remove
Adjust Title Colors
Remove
Adjust Background Colors
Remove
Orientation Control
Mute Sounds
Hide Images
Reading Guide
Stop Animations
Reading Mask
Highlight on Hover
Highlight on Click
Large Cursor
Screen Reader
Keyboard Navigation
Website Accessibility by 
Accessibility Statement
We are committed to ensuring digital accessibility for people with disabilities. We are continually improving the user experience for everyone and applying the relevant accessibility standards and best practices regularly.
Conformance status
The Web Content Accessibility Guidelines (WCAG) define requirements for designers and developers to improve accessibility for people with disabilities. It defines three levels of conformance: Level A, Level AA, and Level AAA.
We have installed an automatic accessibility tool that runs in the background. This tool runs Ai and machine learning to remediate accessibility deficiencies in the HTML code. In addition, it provides an interface that allows visitors to manipulate their browsing experience. The complete toolset aims to assist this site in conforming as closely as possible to the standards by the WCAG 2.1 Level AA.
Additional accessibility considerations
Although our goal is WCAG 2.1 Level AA conformance, we have also applied some Level AAA Success Criteria: Images of text are only used for decorative purposes. Some WCAG 2.1 Level AA requirements are not included in the remediation process as they are outside of the scope of the website source code, including but not limited to video captions.
Measures taken by this website to achieve compliance
-
Complete WCAG 2.1 Level AA website audit and remediation on page load. All on-page elements are scanned and reviewed against our accessibility standards library to ensure compliance. If remediation is required, the element is tagged, and our Ai remediation tool makes necessary, non-invasive corrections on the client-side of the site
-
Auto Image and Link recognition and remediation for content that does not contain alt or title text for users that require screen reader access; descriptions are stored for user adjustment to assist our machine learning algorithms
-
Quick access to search Meriam Website for definitions and pronunciations of words.
-
Colorblindness adjustments to improve distinction between colors for Red-green color blindness (Deuteranomaly, Protanomaly, Protanopia, Deuteranopia), Blue-yellow color blindness (Tritanopia, Tritanomaly), Other color blindness (Achromatopsia, Achromatomaly)
-
Reset fonts to Arial or Implementation of Dyslexia friendly font
-
Ability to Highlight Titles and Links
-
Text Magnification
-
Content, Font, Line Height, Line Spacing Scaling, and Zoom
-
Content alignment including left, center, and right
-
Dark and Light Contrast modes and High Contrast that increases contrast ratio to 135%, and complete inversion of colors
-
Saturation adjustments including High (140% saturation), Low (90% saturation), Monochrome (0% saturation)
-
Complete element color control including Title, Font, and background color adjustments with color-safe color palettes to ensure optimal contrast ratio of 4.5%
-
Ability to stop motion (videos, animated graphics, web element transitions, etc.), hide all images, and mute sounds
-
Simple reading guide or more elaborate page mask to assist users in focusing on-page content
-
Highlight element on hover or focus to ensure both keyboard and mouse users can orient themselves on the focused element
-
A screen reader that reads back page content on highlight
-
Complete keyboard navigation control
-
Aggregated settings into browsing profiles to quickly deploy accessibility configurations for multiple user types.
Compatibility with browsers and assistive technology
We strive to be compatible with the following assistive technologies:
- Google Chrome, Mozilla Firefox, Apple Safari, Opera and Microsoft Edge, JAWS, and NVDA (screen readers), both for Windows and for MAC users.
Technical specifications
Accessibility of this site relies on the following technologies to work with the particular combination of web browsers and any assistive technologies or plugins installed on your computer:
-
HTML
-
WAI-ARIA
-
CSS
-
JavaScript
These technologies are relied upon for conformance with the accessibility standards used.
Notes
While our main goal is to make the entire site accessible to all users, there is a possibility that some pages may not have been discovered or do not have a satisfactory accessibility remediation solution at this time. We are committed to constantly improving the accessibility of this site to ensure it is accessible to all.
Move or Hide the Accessibility Panel
Hide Accessility WidgetHide for 1 DayHide for 1 WeekHide for 1 MonthHide for 1 YearSelect a length of time to hide the accessibility widget. If you wish to show the widget before this period ends, you will need to clear your site cookies.Confirm and Hide
Page Link Tree
Page Landmarks
-
Banner
-
Navigation
-
Main
-
Complementary
-
Navigation
-
Navigation
-
Navigation
-
Navigation
-
Navigation
-
Navigation
-
Contentinfo
-
Navigation
Page Links